In this article, we will discuss the 10 Unstoppable Stocks to Buy and Hold for the Next 5 Years.
As per Ajay Rajadhyaksha, Global Chairman of Research at Barclays, the US job growth has slowed, and China’s economic data have demonstrated weakness. Despite these factors, the firm’s analysts believe that the new economy, driven by AI adoption throughout businesses and consumers, will help sustain global growth.
What’s Next for the US Economy?
The research analysts at Barclays anticipate the global economy to grow 3.1% this year, increasing the estimate marginally from June. However, they expect 2026 growth to be marginally lower. Furthermore, the firm opines that the combination of expected Fed rate cuts and sustained AI momentum is a strong tailwind for risk assets. Its research team favours equities over fixed income for the coming quarter and anticipates that the US stocks will outshine Europe.
Barclays believes that the new economy, which is the modern economic system supported by technology, digital innovation, and knowledge-based industries, has been thriving. In the US and China, technology giants have been demonstrating strong earnings. The global race for AI dominance has been the critical market driver for numerous quarters.
Amidst such trends, we will now have a look at the 10 Unstoppable Stocks to Buy and Hold for the Next 5 Years.
Our Methodology
To list the 10 Unstoppable Stocks to Buy and Hold for the Next 5 Years, we used a screener to shortlist the stocks that have increased significantly over the past 6 months, and in which analysts see upside to. After getting an extensive list, we chose the ones popular among hedge funds, as of Q2 2025. The stocks are arranged in ascending order of their hedge fund sentiments.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
10 Unstoppable Stocks to Buy and Hold for the Next 5 Years
10. Bitdeer Technologies Group (NASDAQ:BTDR)
Number of Hedge Fund Holders: 12
% Gain Over 6 Months: ~96%
Average Upside Potential: ~35.7%
Bitdeer Technologies Group (NASDAQ:BTDR) is one of the Unstoppable Stocks to Buy and Hold for the Next 5 Years. On September 22, Roth Capital lifted the price target on the company’s stock to $40 from $18, while keeping a “Buy” rating, as reported by The Fly. As per the analyst, Bitdeer Technologies Group (NASDAQ:BTDR)’s exposure to high-performance computing and AI might not be the narrative right now, but it will quickly become one over the upcoming 6 – 9 months.
Bitdeer Technologies Group (NASDAQ:BTDR)’s Q2 2025 revenue came in at $155.6 million, reflecting a rise of 56.8% YoY and 121.9% sequentially, thanks to the healthy growth in its self-mining business and external sales of the SEALMINER A2s. Coming to the energy, Bitdeer Technologies Group (NASDAQ:BTDR) continued rapidly building its global power and datacenter infrastructure. On a YTD basis, it energized 361 MW of datacenter capacity for self-mining, bringing the total available electrical capacity to ~1.3 GW. Bitdeer Technologies Group (NASDAQ:BTDR) expects to have more than 1.6 GW by year-end.
9. ABIVAX Société Anonyme (NASDAQ:ABVX)
Number of Hedge Fund Holders: 17
% Gain Over 6 Months: ~1,233.2%
Average Upside Potential: ~23.8%
ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the Unstoppable Stocks to Buy and Hold for the Next 5 Years. On September 25, Citizens JMP lifted the price target on the company’s stock to $114 from $95, while keeping an “Outperform” rating, as reported by The Fly. This announcement follows ABIVAX Société Anonyme (NASDAQ:ABVX) stating that results from the Obefazimod Phase 3 induction trials would be presented next month. As per the firm, the Phase 3 results can reinforce the strength of Obefazimod’s efficacy and increase conviction in the multi-billion-dollar sales potential.
ABIVAX Société Anonyme (NASDAQ:ABVX)’s operating loss rose by EUR 13.7 million to EUR -93.7 million for the 6 months to June 30, 2025, compared to EUR -80.0 million for the same period of the previous year. Operating income, consisting mainly of Research Tax Credit and Subsidies, fell by EUR 4.7 million to EUR 2.1 million for 6 months to June 30, 2025, as compared to EUR 6.8 million for 6 months ending June 30, 2024. The rise in operating loss was due to the operating expenses.
8. Super Group (SGHC) Limited (NYSE:SGHC)
Number of Hedge Fund Holders: 22
% Gain Over 6 Months: ~111%
Average Upside Potential: ~32.4%
Super Group (SGHC) Limited (NYSE:SGHC) is one of the Unstoppable Stocks to Buy and Hold for the Next 5 Years. On September 22, BTIG lifted the price target on the company’s stock to $19 from $14, while maintaining a “Buy” rating, as reported by The Fly. As per the analyst, Super Group (SGHC) Limited (NYSE:SGHC)’s investor day event provided a timely overview of the business at a stage where fundamentals have been improving post-closure of the US sportsbook and iGaming operations. Moving forward, the firm expects runway for revisions, several expansions, and share price upside as investors become familiar with the company’s business.
Super Group (SGHC) Limited (NYSE:SGHC) stated that Q2 2025 was supported by healthy execution throughout the key markets, a full calendar of global sporting events, higher deposits, increased customer retention, and margin expansion. Super Group (SGHC) Limited (NYSE:SGHC)’s Q2 2025 showcased the strongest quarterly financial performance in the company’s history, with revenue rising by 30% YoY and adjusted EBITDA increasing 78% YoY to $157 million, posting a healthy margin of 27%.
7. CRISPR Therapeutics AG (NASDAQ:CRSP)
Number of Hedge Fund Holders: 26
% Gain Over 6 Months: ~87.3%
Average Upside Potential: ~22.3%
CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the Unstoppable Stocks to Buy and Hold for the Next 5 Years. On September 23, analyst Mitchell Kapoor from H.C. Wainwright reiterated a “Buy” rating on the company’s stock, while keeping the price objective at $80.00. As per the firm, the current price target does not yet include any contribution from SRSD107, providing investors with a free call option on the multi-billion-dollar anticoagulation market.
Recently, CRISPR Therapeutics AG (NASDAQ:CRSP) and Sirius Therapeutics announced that the first patient has been dosed in a Phase 2 clinical trial of SRSD107, which is a next-generation, long-acting Factor XI (FXI) siRNA for preventing venous thromboembolism (VTE) in patients undergoing total knee arthroplasty (TKA). Notably, CRISPR Therapeutics AG (NASDAQ:CRSP)’s M.D. and Chief Medical Officer highlighted that SRSD107 provides the potential to reduce pathological thrombosis while, at the same time, reducing the bleeding risk, with sustained but reversible pharmacodynamic effects and the possibility of infrequent dosing.
RGA Investment Advisors, an investment management company, released its Q2 2025 investor letter. Here is what the fund said:
“After commercial approval of Casgevy, CRISPR Therapeutics AG (NASDAQ:CRSP) shares traded over $90. At their worst in the April crash, shares changed hands at $30, a 2/3rd discount to their post-approval peak. The trade war would ultimately have a negligible impact on CRSP, but shares dropped nearly 30% in the Spring collapse. This made little sense to us, especially given the substantial cash balance the company has built with prudent financings along the way.
When we bought shares of CRSP, the company’s Enterprise Value was below $800m, boasting over $1.8 billion in net cash. As the name would suggest, CRSP is a first-mover and leader in the Cell and Gene Therapy (CGT) space and the first to bring a life-changing gene editing therapy to FDA approval and commercial availability. For reference, CRISPR is a gene-editing technology that enables scientists to precisely alter DNA within living organisms by using a guide RNA and an enzyme (like Cas9) to cut and modify specific genetic sequences. We know the company well from following a basket of cell and gene therapy companies.
CRSP’s management has excelled at balancing capital discipline with R&D ambition. Now, with a commercial product and arguably the strongest balance sheet in its space, CRSP is in an enviable position, affording the opportunity to lean into its pipeline, while competitors retrench to conserve cash. We believe the company will retain over $900 million in cash by the time it turns cash flow positive. In essence, we’re buying Casgevy at a steep discount and getting the pipeline and cash for free. This is one of the more asymmetric setups we’ve encountered.”
6. Zeta Global Holdings Corp. (NYSE:ZETA)
Number of Hedge Fund Holders: 34
% Gain Over 6 Months: ~55.3%
Average Upside Potential: ~30.5%
Zeta Global Holdings Corp. (NYSE:ZETA) is one of the Unstoppable Stocks to Buy and Hold for the Next 5 Years. On September 23, DA Davidson lifted the price target on the company’s stock to $27 from $25, while keeping a “Buy” rating, as reported by The Fly. The firm remains positive on Zeta Global Holdings Corp. (NYSE:ZETA)’s increasing role as a key component of the long-term growth engine. Furthermore, it characterized the agency business as a misunderstood component of the narrative and identified upside to 2025 and 2026 revenue estimates, considering the company’s continued success in winning new clients and expansion of the existing agency relationships.
The second quarter ended June 30, 2025 was supported by demand for Zeta Global Holdings Corp. (NYSE:ZETA)’s AI-powered marketing platform. Furthermore, the company believes that its AI-driven momentum, backed by the Zeta Answers release, new Zeta Marketing Platform deployments, agency expansions, and OneZeta wins, provides conviction that the company remains well-placed to capture more market share.
5. GDS Holdings Limited (NASDAQ:GDS)
Number of Hedge Fund Holders: 37
% Gain Over 6 Months: ~57.3%
Average Upside Potential: ~20%
GDS Holdings Limited (NASDAQ:GDS) is one of the Unstoppable Stocks to Buy and Hold for the Next 5 Years. On September 19, Raymond James reiterated its “Strong Buy” rating on the company’s stock with a price target of $53.00, highlighting potential growth catalysts. The firm opines that GDS Holdings Limited (NASDAQ:GDS) remains well-positioned to benefit from accelerating growth in China’s data center market once AI chips are more widely available.
In Q2 2025, GDS Holdings Limited (NASDAQ:GDS) accelerated the delivery of its backlog while maintaining a selective approach to new orders. The successful IPO of its C-REIT on the Shanghai Stock Exchange reflects a key strategic milestone. Moving forward, GDS Holdings Limited (NASDAQ:GDS) remains well-positioned to capture new business opportunities in Tier 1 markets, thanks to the AI evolution. In Q2 2025, its net revenue came in at RMB2,900.3 million (US$404.9 million), reflecting 12.4% YoY growth, which was mainly because of the continued ramp-up of its data centers.
Baron Funds, an investment management company, released its Q1 2025 investor letter. Here is what the fund said:
“GDS Holdings Limited (NASDAQ:GDS) is a leading data center operator in Tier 1 cities in China, with a growing presence across Asia through its now de-consolidated international business, DayOne. Shares performed well in February, driven by early signs of AI-related demand – highlighted by a major 152-megawatt deal with a leading cloud hyperscaler, Alibaba – and optimism around accelerating growth in its international business. Investor sentiment was further supported by stronger-than-expected capex from Alibaba, signaling a potential rebound in hyperscale demand, and by the monetization of select assets at premium valuations through a REIT transaction anchored by one of China’s largest life insurers. However, shares gave back gains in March as concerns resurfaced around potential elevated capital needs to serve a higher level of demand, as well as broader macro risks. Specifically, investors grew increasingly wary of renewed threats on further NVIDIA chip restrictions, overall tightening trade restrictions, and the uncertain trajectory of U.S. – China geopolitical relations. Despite near-term volatility, we remain constructive on the stock and fundamentals. GDS trades at an undemanding valuation, with clear catalysts ahead: accelerating revenue, progress toward deleveraging, and significant embedded value in its international operations. With durable secular tailwinds in cloud computing and AI infrastructure, and deep relationships with leading technology firms in China and the U.S., GDS remains well positioned for long-term value creation.”
4. Nebius Group N.V. (NASDAQ:NBIS)
Number of Hedge Fund Holders: 45
% Gain Over 6 Months: ~425.0%
Average Upside Potential: ~42.1%
Nebius Group N.V. (NASDAQ:NBIS) is one of the Unstoppable Stocks to Buy and Hold for the Next 5 Years. On September 22, the company announced that, in connection with its previously announced underwritten public offering of Class A ordinary shares, the underwriters exercised in full their option to purchase an additional 1,621,621 shares. This has been done at the offering price of $92.50, less underwriting discounts and commissions, resulting in Nebius Group N.V. (NASDAQ:NBIS)’s aggregate gross proceeds of ~$1.15 billion.
The initial closing occurred on September 15, at which time Nebius Group N.V. (NASDAQ:NBIS) also closed an offering of convertible notes due 2030 and 2032 to qualified institutional buyers. The aggregate proceeds of both offerings are ~$4.3 billion. Elsewhere, Nebius Group N.V. (NASDAQ:NBIS) announced an agreement to deliver AI infrastructure to Microsoft. Notably, the deal economics are attractive in their own right, and the deal will help Nebius Group N.V. (NASDAQ:NBIS) to ramp up the growth of its AI cloud business even further in 2026 and beyond.
3. Celsius Holdings, Inc. (NASDAQ:CELH)
Number of Hedge Fund Holders: 52
% Gain Over 6 Months: ~57.2%
Average Upside Potential: ~24.9%
Celsius Holdings, Inc. (NASDAQ:CELH) is one of the Unstoppable Stocks to Buy and Hold for the Next 5 Years. On September 26, Citi lifted the price target on the company’s stock to $73 from $60, keeping a “Buy” rating after Celsius Holdings, Inc. (NASDAQ:CELH) stated that Alani Nu will move to PepsiCo’s distribution system in the U.S. and Canada. Also, Pepsi raised its stake in Celsius to ~11%. Notably, the firm views the agreement as favourable for the company as it scales the Alani Nu brand.
With the momentum building across the energy category, Celsius Holdings, Inc. (NASDAQ:CELH)’s brands continue to lead, fueling household penetration, expanding shelf space, and outperforming expectations. For the 3 months ended June 30, 2025, Celsius Holdings, Inc. (NASDAQ:CELH)’s revenue came in at ~$739.3 million as compared to $402.0 million for the prior-year period, demonstrating 84% growth. This rise stemmed mainly from $301.2 million of revenue from the Alani Nu® brand, which it acquired on April 1, 2025.
Alani Nu saw record sales thanks to the strong limited-time-offer (LTO) innovation performance and organic growth throughout the brand’s core flavors. Carillon Tower Advisers, an investment management company, released its Q1 2025 investor letter. Here is what the fund said:
“Celsius Holdings, Inc. (NASDAQ:CELH) develops, markets, sells, and distributes functional fitness and lifestyle beverages. The stock performed well during the period, driven by Celsius’ now-completed acquisition of Alani Nu, a fast-growing energy drink brand that is expected to boost the combined companies’ market share. Additionally, the company’s core business improved sequentially through March and started the second quarter poised to return to positive growth.”
2. Affirm Holdings, Inc. (NASDAQ:AFRM)
Number of Hedge Fund Holders: 70
% Gain Over 6 Months: ~66.0%
Average Upside Potential: ~28%
Affirm Holdings, Inc. (NASDAQ:AFRM) is one of the Unstoppable Stocks to Buy and Hold for the Next 5 Years. On September 25, Citizens JMP reiterated a “Market Outperform” rating on the company’s stock with a price objective of $105.00. The firm highlighted a strong growth runway ahead for the buy-now-pay-later (BNPL) provider, demonstrating Affirm Holdings, Inc. (NASDAQ:AFRM)’s broader range of retail partners compared to its competitors.
Furthermore, the firm views Affirm Holdings, Inc. (NASDAQ:AFRM)’s platform as differentiated due to its broader offerings, which include short-term Pay-in-X financing and more traditional installment loans, which the firm believes are more suitable for a larger set of consumer goods. For Q1 2026, the company expects GMV of between $10.10 billion – 10.40 billion, and revenue of $855 million – $885 million. Affirm Holdings, Inc. (NASDAQ:AFRM) expects an operating margin of between 1% – 3%. In Q4 2025, its total revenue grew 33% to $876 million.
1. NVIDIA Corporation (NASDAQ:NVDA)
Number of Hedge Fund Holders: 235
% Gain Over 6 Months: ~67.8%
Average Upside Potential: ~20.3%
NVIDIA Corporation (NASDAQ:NVDA) is one of the Unstoppable Stocks to Buy and Hold for the Next 5 Years. On September 27, Jefferies analyst Blayne Curtis lifted the price target on the company’s stock to $220 from $205, while keeping a “Buy” rating, as reported by The Fly. After NVIDIA Corporation (NASDAQ:NVDA) announced a partnership with OpenAI to deploy 10GW of Nvidia systems, the analyst highlighted that management made clear that this partnership reflects incremental demand and that it doesn’t overlap with existing OpenAI plans with Oracle or Microsoft.
Talking about the partnership, NVIDIA Corporation (NASDAQ:NVDA) stated that it plans to invest up to $100 billion in OpenAI progressively as each gigawatt is deployed. Notably, the first gigawatt of NVIDIA systems is expected to be deployed in H2 2026 on the NVIDIA Vera Rubin platform. Elsewhere, NVIDIA Corporation (NASDAQ:NVDA) and Intel Corporation collaborated to develop multiple generations of custom data center and PC products, which accelerate applications and workloads throughout hyperscale, enterprise, and consumer markets.
Chautauqua Capital Management, a division of Baird Asset Management, is a boutique investment firm that released its Q2 2025 investor letter for the “Baird Chautauqua International and Global Growth Fund”. Here is what the fund said:
“NVIDIA Corporation (NASDAQ:NVDA) reported first quarter results that were extremely solid. The company took a write-down on China-specific datacenter products and flushed out any future China contributions from their guidance, following the new export restrictions introduced in April. Demand commentary ex China was extremely encouraging—Nvidia is outgrowing expectations despite supply constraints and outgrowing competing ASIC products by a large margin. We have been underweight Nvidia relative to the benchmark, which was up 46% in the quarter, given our short-to medium-term concerns that the feverish AI datacenter build may be resulting in overcapacity, which has not come to bear.”
While we acknowledge the potential of NVDA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NVDA and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
